MENLO PARK, Calif.--(BUSINESS WIRE)--Apr. 7, 2022-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced that company management will participate in two upcoming investor conferences in April.

Details of the events are as follows:

Canaccord Genuity 2022 Horizons in Oncology Virtual Conference, April 14, 2022
Chen Schor, President and Chief Executive Officer, will participate in a panel discussion titled, “Gamma Delta T-cells: A differentiated approach” on Thursday, April 14, 2022, at 12:00 PM ET.

2022 Jefferies Biotech on the Bay Summit, April 26-27, 2022
Adicet’s management team will participate in 1x1 investor meetings at the St. Regis, Bal Harbour in Miami, Florida on April 27, 2022.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with CAR and T cell receptor-like targeting moieties to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http://www.adicetbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220407005696/en/

Adicet Bio., Inc.
Investor and Media Contacts

Anne Bowdidge
abowdidge@adicetbio.com

Janhavi Mohite
Stern Investor Relations, Inc.
212-362-1200
janhavi.mohite@sternir.com

Source: Adicet Bio, Inc.